-
Article
Checkpoint inhibitors and anti-angiogenic agents: a winning combination
The combination of immune checkpoint inhibitors and anti-angiogenic agents is a promising new approach in cancer treatment. Immune checkpoint inhibitors block the signals that help cancer cells evade the immun...
-
Article
Checkpoint inhibitors in a marriage: consented or arranged?
There is currently a strong development of therapeutic combinations with checkpoint inhibitors (CPIs). The most promising combinations with CPIs concern anti-angiogenic agents and BRAF/MEK inhibitors. The timi...
-
Article
COVID-19 vaccination and cancer immunotherapy: should they stick together?
The combination of COVID-19 vaccination with immunotherapy by checkpoint inhibitors in cancer patients could intensify immunological stimulation with potential reciprocal benefits. Here, we examine more closel...
-
Article
Open AccessMore light on cancer and COVID-19 reciprocal interaction
Cancer patients are vulnerable to COVID-19 with consequences on treatment delays and on mortality rate. This Comment explores the interaction between COVID-19 and cancer with attention paid to the modulation b...
-
Article
Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
Corrections are needed to the original version of this article.
-
Article
Open AccessAuthor Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and bioindustry
-
Article
Open AccessHyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
Hyperprogressive disease (HPD), an unexpected acceleration of tumor growth kinetics, is described in cancer patients treated with anti-PD-1/anti-PD-L1 agents. Here, our aim was to take into consideration the h...
-
Article
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
Background Checkpoint inhibitors bring marked benefits but only in a minority of patients and may also be associated with severe adverse events. Treatment outcome still cannot be faithfully predicted. The followi...
-
Article
In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF V600E mutation status and together with hypoxia-related proteins predicts aggressive behavior
BRAF V600E causes upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1), which promotes cell invasion in papillary thyroid carcinoma...
-
Article
Etiology of Crohn’s disease: many roads lead to autophagy
Crohn’s disease is a complex multifactor diseases that occur in individuals with genetic predisposition in whom environmental and microbial triggers cause a deleterious chronic immune response. Susceptibility ...
-
Article
A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease
Paul Hofman and colleagues show that a synonymous variant in IRGM, previously associated with risk of Crohn's disease, alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy. These ...
-
Article
Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility
The term thyroid tumours of uncertain malignant potential (TT-UMP) has been proposed for a subgroup of follicular-patterned thyroid tumours for which benignancy or malignancy cannot be assessed with certainty....
-
Chapter
Apoptosis and Tumor Cell Death in Response to HAMLET (Human α-Lactalbumin Made Lethal to Tumor Cells)
HAMLET (human a-lactalbumin made lethal to tumor cells) is a molecular complex derived from human milk that kills tumor cells by a process resembling programmed cell death. The complex consists of partially un...
